A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Clinical trial NCT02773030 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02773030
- Sponsor
- Celgene
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-14
- Primary completion
- 2024-05-09
- Enrollment
- 466
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.